author-photo

Vikki Flemington

AstraZeneca

16

Papers

168

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Challenges and Opportunities in Cancer Drug Resistance.

2020 Chemical Reviews
Show All
- Source
- Cite
- Save
Citations (37)
Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of non-small cell lung cancer (NSCLC)

2019 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (15)
Abstract 1856: Combination of the novel ERK inhibitor AZD0364 with the MEK inhibitor selumetinib significantly enhances antitumor activity in KRAS mutant tumor models

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 4913: A PK/PD model quantitatively describes inhibition and down-regulation of p90RSK by ERK inhibitor AZD0364

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1647: Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.

2017 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (32)
Human Erk2 with an Erk1/2 inhibitor

2017
Show All
- Source
- Cite
- Save
Citations (0)
Human ERK2 in complex with an inhibitor

2015
Show All
- Source
- Cite
- Save
Citations (0)
Human ERK2 in complex with an irreversible inhibitor

2015
Show All
- Source
- Cite
- Save
Citations (0)
Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation

2014 Chemical Communications
Show All
- Source
- Cite
- Save
Citations (21)